Moderna, Inc.

(NASDAQ Global Select)

Top News rankings and signal summaries are processed using AI and may contain errors.

21
Bullish +75

Moderna (MRNA) Gets Phase 3 Melanoma Vaccine Validation At ESMO And NEJM

Clinical trial results Drug approval AI-generated analysis

Moderna (MRNA) and Merck reported positive Phase 3 clinical trial data for their combination therapy of an individualized mRNA melanoma vaccine, intismeran, and KEYTRUDA at the ESMO 2026 conference. The results were accepted for publication in The New England Journal of Medicine, providing peer-reviewed validation...

Bullish Signals

  • Reduced recurrence risk 42% vs KEYTRUDA in high-risk melanoma.
22
Somewhat Bearish -45

Moderna Tumbles 7% as Cancer Vaccine Selloff Deepens; BioNTech Falls 3%, Pfizer Holds Steady

Clinical trial results Company update Regulatory submission AI-generated analysis

Moderna (MRNA) shares fell 7% to $185.74 following the release of late-stage trial data for its personalized melanoma vaccine, Intismeran autogene. While the drug met its primary endpoint of reducing return or death risk when combined with Merck's Keytruda, it significantly underperformed on distant metastasis...

Bullish Signals

  • Melanoma vaccine met primary trial goal with Keytruda.
  • Cleared main hurdle for flagship cancer program.

Bearish Signals

  • Shares fell 7% after distant metastasis results missed expectations.
  • Cancer trial miss outweighs primary goal win, reducing upside.
  • High concentration risk as business relies on mRNA medicines.
23
Somewhat Bearish -45

Moderna stock crashes as leaked melanoma data threatens its record August rally - Yahoo Finance

Clinical trial results AI-generated analysis

Moderna (MRNA) stock experienced a significant intraday decline of up to 26% and closed down more than 17%, marking its worst trading day since August 20. This sharp drop occurred after leaked data from a late-stage melanoma vaccine trial circulated ahead of the official results...

Bullish Signals

  • Vaccine + Keytruda cut recurrence/death risk by 42%.
  • Earlier trial showed 49% risk reduction with different patients.

Bearish Signals

  • Stock fell 26% intraday, worst day since August.
  • $17B market value vanished after trial leak.
24
Bullish +75

Why Moderna Stock Surged Today - Yahoo Finance

Clinical trial results Regulatory approval AI-generated analysis

Moderna (NASDAQ:MRNA) shares surged more than 14% on Friday following reports of a major new cancer research initiative. The National Institutes of Health plans to launch a campaign in December to fast-track cancer treatment research, aiming to replicate the success seen with early-stage Covid-19 vaccine...

Bullish Signals

  • Shares jumped 14% on major cancer research initiative reports.
  • NIH plans fast-track cancer treatment research in December.
  • Public-private partnership will accelerate scientific discoveries.
  • AI and mRNA tech enable tailored patient treatments.
  • Co-developed therapy with Merck increased time before cancer return.
  • New initiative could accelerate development timelines and profits.
25
Bullish +75

Moderna stock heads into the open after a 12.27 percent gain

AI-generated analysis

Moderna Inc. (MRNA) shares surged 12.27 percent to close at USD 172.94 on September 21, 2026, significantly outperforming the Nasdaq Composite's 2.26 percent gain. The stock traded in a range between USD 154.04 and USD 176.86, reaching a new 52-week high with trading volume of...

Bullish Signals

  • Stock surged 12.27% to close at USD 172.94.
  • Shares hit new 52-week high of USD 176.86.
  • Three intismeran abstracts accepted for ESMO Congress 2026.
  • Phase 3 melanoma results due late October.